Olpadronate: a new amino-bisphosphonate for the treatment of medical osteopathies

Bibliography

• DELMAS PD: The management of Paget's disease of bone. New Eng. J. Med. (1997) 336:558–566.
   PubMed Web of Science ®Google Scholar
• MUNDY GR, GUISE TA: Hypercalcaemia of malignancy. Am. J. Med. (1997) 103:134–145.
   PubMed Web of Science ®Google Scholar
• SCHER HI, YAGODA A: Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibi-tors. Am. J. Med. (1987) 82 (Suppl. 2A):6–28.
   Google Scholar
• ROLDAN EJA, PEREZ LLORET A: El uso de pamidronato dim:Idle° en osteolisis malignas. Tumour (1990) 3:118–122.
   Google Scholar
• KHALTAEV NG: Osteoporosis as growing problem -WHO perspectives. Scand.J. Rheumatol. (1996) 25 (Suppl. 103):129–133.
   Google Scholar
• KANIS JA, McCLOSKEY EV: Epidemiology of vertebralosteoporosis. Bone (1992) 13:S1–S10.
   PubMedGoogle Scholar
• MELTON III: Epidemiology of hip fractures: implica-tions of the exponential increase with age. Bone (1996) 1 8 (Suppl.) :121S–125S.
   Google Scholar
• MACCAGNO A, DI GIORGIO E, ROLDAN EJA, CABALLERO LE, PEREZ LLORET A: Double blind radiological assess-ment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scan. J. Rheumatol. (1994) 23:211–214.
   PubMed Web of Science ®Google Scholar
• EGGELMEIJER F, PAPAPOULOS SE, VAN PAASSEN HC etal: Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year ran-domized, double blind trial. Arthritis Rheum. (1996) 39:396–402.
   PubMed Web of Science ®Google Scholar
• BIJVOET OLM, VELLENGA CJLR, HARINCK HIJ: Paget'sDisease of Bones: Assessments, Therapy, and Secon-dary Prevention. In Proc. Simp. Clinical Disorders of Bone and Mineral Metabolism. Michigan, USA (1988):525–542.
   Google Scholar
• SIRIS E, WEINSTEIN RS, ALTMAN R et al.: Comparativestudy of alendronate versus etidronate for the treat-ment of Paget's disease of bone. J. Clin. Endocrinol Me-tab. (1996) 81:961–967.
   PubMed Web of Science ®Google Scholar
• HOSKING DJ, EUSEBIO RA, CHINES AA: Paget's diseaseof bone: reduction of disease activity with oral rise-dronate. Bone (1998) 22:51–55.
   PubMed Web of Science ®Google Scholar
• ROUX C, GENNARI C, FARRERONS J et al.: Comparativeprospective study, double blind, multicenter study of the efficacy of tiludronate and etidronate in the treat-ment of Paget's disease of bone. Arthitis. Rheum. (1995) 38: 851–858.
   PubMed Web of Science ®Google Scholar
• KANIS JA. Rationale for the use of bisphosphonates inbreast cancer. Acta Oncol. (1996) 35:561–567.
   Web of Science ®Google Scholar
• VAN HOLTEN-VERZANVOORT ATM, PAPAPOULOS SE. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer. Me-dicina (Buenos Aires) (1997) 57 (Suppl. 0:109–113.
   Google Scholar
• BARREIRA JC, MESSINA OD, MALDONADO COCCO JA,ROLDAN EJA: Site-dependent bone mineral density re-sponse to oral pamidronate and calcium in postmeno-pausal osteoporosis: a preliminary report. Clin. Rheumatol. (1997) 16:346–352.
   PubMed Web of Science ®Google Scholar
• FROMM GA, VEGA E, PLANTALECH L, GALICH MA, MAUTALEN CA: Differential action of pamidronate on trabecular and cortical bone in women with involu-tional osteoporosis. Osteoporosis Int. (1991) 1:129–133.
   PubMedGoogle Scholar
• PAPAPOULOS SE: The role of bisphosphonates in thetreatment and prevention of osteoporosis. Am. J. Med. (1993) 95 (Supp1.5A):48S–52S.
   Google Scholar
• ZANCHETTA JR, SPIVACOW RF, BOGADO C et al: Usoprolongado, hasta 6 altos, de un amino-bisfosfonato oral en pacientes con osteoporosis establecida. Me-dicina (Buenos Aires) (1997) 57 (Suppl. 0:37–44.
   Google Scholar
• LIBERMAN UA, WEISS SR, BROLL J et al.: Effect of oral al-endronate on bone mineral density and the incidence of fractures in posmenopausal women. NewEng. J. Med. (1995) 333:1437–1443.
   PubMed Web of Science ®Google Scholar
• ANONIMUS: Negative phase II results for long termrisedronate in osteoporosis. Prous. Sci. Daily Essentials (1997):1198.
   Google Scholar
• DE GROEN PC, LUBBE DF, HIRSCH LJ et al.: Esophagitisassociated with the use of alendronate. NewEngl. J. Med. (1996) 335:1016–1021.
   PubMed Web of Science ®Google Scholar
• ULLA MR, ARAUJO GL, GHIGLIONE F et al.: Urinary freepyridinolines and bone mass assessments of alen-dronate response in postmenopausal women. J. Bone MM. Res. (1997) 12 (Suppl. 1):S468.
   Google Scholar
• ULLA MR, ARAUJO G, GIGLIONE F et al.: Efectos del alen-dronato oral, la hormonoterapia de reemplazo y la combinación de ambos sobre la masa ()sea en mujeres posmenopausicas. Medicina (Buenos Aires) (1997) 57 (Suppl. 0:49–55.
   Google Scholar
• LINDSAY R, BUSH TL, GRADY D, SPEROFF L, LOBO RA:Therapeutic controversy. Estrogen replacement in menopause. J. Clin. Endocrinol. Metab. (1996) 81:3829–3838.
   PubMed Web of Science ®Google Scholar
• GARTON M, REID D, RENNIE E: The climateric, osteopo-rosis and hormone replacement; views of women aged 45-49. Maturitas (1995) 21:7–15.
   PubMed Web of Science ®Google Scholar
• DELMAS PD, BJARNASON NH, MITLAK BH et al.: Effects ofraloxifene on bone mineral density, serum choles-terol concentrations, and uterine endometrium in posmenopausal women. New Eng. J. Med. (1997) 337:1641–1647.
   PubMed Web of Science ®Google Scholar
• ADAMI S, PASSERI M, ORTOLANI S et al.: Effects of oral al-endronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone (1995) 17:383–390.
   PubMed Web of Science ®Google Scholar
• PAK CYC, SAKHAEE K, ADAMS-HUET B et al: Treatmentof postmenopausal osteoporosis with slow-release so-dium fluoride. Ann. Intern. Med. (1995) 123:401–408.
   PubMed Web of Science ®Google Scholar
• RIGGS BL, HODGSON SF, O'FALLON WM et al.: Effect offluoride treatment on the fracture rate in postmeno-pausal women with osteoporosis. New Eng. J. Med. (1990) 322:802–809.
   Google Scholar
• SOGAARD CH, MOSEKILDE L, RICHARDS A, MOSEKILDE L: Marked decrease in trabecular bone quality after five years of sodium fluoride therapy - assessed by biome-chanical testing of iliac crest bone biopsies in osteo-porotic patients. Bone (1994) 15:393–399.
   PubMed Web of Science ®Google Scholar
• McKANE WR, KHOSLA S, EGAN KS et al: Role of calciumintake in modulating age-related increases in parathy-roid function and bone resorption. J. Clin. Endocrinol Metab. (1996) 81:1699–1703.
   PubMed Web of Science ®Google Scholar
• NAGANT DE DEUXCHAISNES C, DEVOGELAER JP, ESSE-LINCK W et al: Non hormonal treatment of osteoporo-sis. Brit. Med. J. (1983) 286:1647–1648.
   PubMedGoogle Scholar
• ROLDAN EJA, Los bisfosfonatos. Estructura quimica, farmacologia y toxicologia de los bisfosfonatos de lra, 2da y 3ra generaci6n. Rev. Arg. Endocrinol. Metab. (1987) 24:2–8.
   Google Scholar
• GERTZ BJ, HOLLAND SD, KLINE WF et al: Studies of the oral bioavailability of alendronate. Gun. Pharmacol. Ther. (1995) 58:288–298.
   PubMed Web of Science ®Google Scholar
• LANDMAN JO, HAMDY NAT, PAUWELS EKJ, PAPAPOU-LOS SE: Skeletal metabolism in patients with osteopo-rosis after discontinuation of long-term treatment with oral pamidronate. J. Clin. Endocrinol Metab. (1995) 80:3465–3468.
   PubMed Web of Science ®Google Scholar
• ROLDAN EJA, KERZBERG EM, CASTELLI A, PEREZ LLORET A: Efecto de bajas dosis de pamidronato (APD) oral so-bre la calcaemia de pacientes osteopénicas u osteo-porciticos. Medicina (Buenos Aires) (1996) 56:133–137.
   PubMed Web of Science ®Google Scholar
• ZANCHETTA JR, PLOTKIN H, ROLDAN EJA: Mineral den-sity gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinu-ance. Calcif Tissue Int. (1996) 59:70–72.
   PubMed Web of Science ®Google Scholar
• ORR-WALKNER B, WATTLE DJ, EVANS MC, REID IR: Ef-fects of prolonged bisphosphonate therapy and its dis-continuation on bone mineral density in post-menopausal osteoporosis. Clin. Endocrinol. (1997) 46:87–92.
   PubMed Web of Science ®Google Scholar
• HOSKING DJ, EUSEBIO RA, CHINES AA: Paget's diseaseof bone: reduction of disease activity with oral rise-dronate. Bone (1998) 22:51–55.
   PubMed Web of Science ®Google Scholar
• CHINES A, BEKKER P, CLARKE P, HOSKING D: Reductionof bone pain and alkaline phosphatase in patients with severe Paget's disease of bone following treat-ment with risedronate. J. Bone Min. Res. (1996) 11 (Suppl. 1):S371.
   Google Scholar
• ARDEN-CORDONE M, SIRIS ES, LYLES KW et al: Antire-sorptive effect of a single infusion of microgram quan-tities of zoledronate in Paget's disease of bone. Calcif Tissue Int. (1997) 60:415–418.
   PubMed Web of Science ®Google Scholar
• RALSTON SH, THIEBAUD D, STEINHAUER EU et al: Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Brit. J. Cancer (1997) 75:295–300.
   PubMed Web of Science ®Google Scholar
• ERDTSIECK RJ, POLS HAP, VALK NK et al.: Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo con-trolled trial. Chn. Endocrinol. (1995) 43:557–565.
   PubMed Web of Science ®Google Scholar
• FROST HM: Osteoporosis treatment: quo vadis? (A brief overview). Medicina (Buenos Aires) (1997) 57 (Suppl. 1)119–126.
   Google Scholar
• ROLDAN EJA: Editorial. Osteoporosis: una enfermedad con problemas de definiciones. Medicina (Buenos Aires) (1995) 55/2:625–628.
   Google Scholar
• FROST HM: Defining osteopenia and osteoporoses: an-other view (with insights from a new paradigm). Bone (1997) 20:385–391.
   PubMed Web of Science ®Google Scholar
• FERRETTI JL, FROST HM, GASSER JA et al.: Perspectives on osteoporosis research: its focus and some insights of a new paradigm. Calcif Tissue Int. (1995) 57:399–404.
   PubMed Web of Science ®Google Scholar
• MULLENDER MG, HUISKES R: Osteocytes and bone lin-ing cells: which are the best candidates for mechano-sensors in cancellous bone. Bone (1997) 20:527–532.
   PubMed Web of Science ®Google Scholar
• VAN DER PLAS A, NIJWEIDE PJ: Cell-cell interactions inthe osteogenic compartment of bone. Bone (1988) 9:107–111.
   PubMed Web of Science ®Google Scholar
• HUI SL, SLEMENDA CW, JOHNSTON CC Jr: Baseline meas-urements of bone mass predicts fracture in white women. Ann. Intern. Med. (1989) 111:355–361.
   PubMed Web of Science ®Google Scholar
• BURR DB, FORWOOD MR, FYHRIE DP et al: Bone micro-damage and skeletal fragility in osteoporotic and stress fractures. J. Bone Min. Res. (1997) 12:6–15.
   PubMed Web of Science ®Google Scholar
• DUNCAN RL, TURNER CH: Mechanotransduction andthe functional response of bone to mechanical strain. Calcif Tissue Int. (1995) 57:344–358.
   PubMed Web of Science ®Google Scholar
• ROLDAN EJA, MONDELO N, PICCINNI E, PELUFFO V, MONTUORI E. Olpadronic acid sodium salt - treatment for Paget's bone disease, treatment for osteoporosis. Drug Future (1995) 20:1123–1127.
   Google Scholar
• BOONEKAMP PM, LOWIK CWGM, VAN DER WEE-PALSLJA, VAN WIJK-VAN LENNEP MML, BIJVOET OLM: En-hacement of the inhibitory action of APD on the trans-formation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner. (1987) 2:29–42.
   PubMedGoogle Scholar
• BOONEKAMP PM, VAN DER WEE-PALS LJA, VAN WIJK-VAN LENNEP MML, THESING CW, BIVOET OLM: Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. (1986) 1:27–39.
   PubMedGoogle Scholar
• VAN BEEK E, HOEKSTRA M, VAN DE RUIT M, LOWIK C,PAPAPOULOS S: Structural requirements for bisphos-phonates actions in vitro. J. Bone Miner. Res. (1994) 12:1875–1882.
   Google Scholar
• FERRETTI JL: Biomechanical Properties of Bone. InBone Densitometry and Osteoporosis. Genant HK, Guglielmi G, Jergas M (Eds.), Springer Verlag, Berlin, Germany (1997) :143–161.
   Google Scholar
• VAN DER PLUIJM G, VLOEDGRAVEN H, VAN BEEK E et al:Bisphosphonates inhibit the adhesion of breast can-cer cells to bone matrices in vitro. Clin. Invest. (1996) 98:698–705.
   Google Scholar
• BROWN RJ, VAN BEEK E, WATTS DJ, LOWIK CWGM, PA-PAPOULOS SE: Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. J. Bone Min. Res. (1998) 13:253–258.
   PubMed Web of Science ®Google Scholar
• MONDELO N, PARMA MD, PELUFFO VA et al: Efectos ex-perimentales de olpadronato y pamidronato sobre la masa &ea. Medicina (Buenos Aires) (1997) 57 (Suppl. 1)17–24.
   Google Scholar
• ZENI S, GOMEZ ACOTTO C, MAUTALEN C: The effect of olpadronate in ovariectomized thyroxine-treated rats. Bone (1997) 21:329–333.
   PubMed Web of Science ®Google Scholar
• MONTUORI E, MONDELO N, ROLDAN EJA, ORDUNA ME, ZANCHETTA JR: Aminobisphophonates: dose depend-ant inhibition of bone loss on compact and trabecular bone mass of osteoporotic rats. Bone Miner. (1992) 17 (Supp1.1) :180. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(9)
   Google Scholar
• FERRETTI JL, CAPOZZA RF, MONDELO N et al: Interrela-tionships between densitometric, geometric and me-chanical properties of rat femurs. Inferences concerning mechanical regulation of bone modeling. J. Bone Miner. Res. (1993) 8:1389–1396.
   PubMed Web of Science ®Google Scholar
• FROST HM (Ed.): Introduction to a new skeletal physiol-ogy. I. Bone and bones. The Pajaro Group, Pueblo, CO (1995).
   Google Scholar
• FROST HM, FERRETTI JL, JEE WSS: Perspectives: someroles of mechanical usage, muscle strength, and the mechanostat in skeletal physiology, disease, and re-search (Editorial). Calcif Tissue InL (1998) 62:1–7.
   PubMed Web of Science ®Google Scholar
• FERRETTI JL: Perspectives of pQCT technology associ-ated to biomechanical studies in skeletal research em-ploying rat models. Bone (1995) 17: 3535-364S.
   Google Scholar
• FERRETTI JL: Effects of Bisphosphonates on Bone Bio-mechanics. In: Bisphosphonate on Bones. Bijvoet OLM, Canfield R, Fleisch H, Russell RGG (Eds.), Elsevier, Amster-dam, Holland (1995):211–229.
   Google Scholar
• FERRETTI JL, CAPOZZA RF, ZANCHETTA JR: Mechanicalvalidation of a tomographic (pQCT) index for the non-invasive assessment of rat femur bending strength. Bone (1996) 18:97–102.
   PubMed Web of Science ®Google Scholar
• FERRETTI JL: Noninvasive assessment of bone architec-ture and biomechanical properties in animals and hu-mans employing pQCT technology. J. Jap. Soc. Bone Morphom. (1997) 7:115–125.
   Google Scholar
• FERRETTI JL, MONDELO N, PELUFFO V et al.: Sub-chroniceffects of high doses of mildronate on femur densi-tometric (DEXA), tomographic (pQCT) and mechani-cal properties in young rats. Bone Miner (1994) 25 (Supp1.2) :S12.
   Google Scholar
• FERRETTI JL, MONDELO N, CAPOZZA RF et al.: Effects oflarge doses of olpadronate (dimethyl-pamidronate) on mineral density, cross-sectional architecture, and mechanical properties of rat femurs. Bone (1995) 16:285S–2935.
   Google Scholar
• COINTRY GR, MONDELO N, PELUFFO V et al.: Effects ofhigh oral doses of olpadronate on mouse femur mass, architecture and mineralization. A tomographic (pQCT) study. Bone (1996) 19:135S.
   Google Scholar
• COINTRY GR, MONDELO N, ZANCHETTA JR et al.: Intra-venous olpadronate restores ovariectomy-affected bone strength. A mechanical, densitometric and tomo-graphic (pQCT) study. Bone (1995) 17 (Supp1.4):S373–378.
   Google Scholar
• FERRETTI JL, MONDELO N, PELUFFO V et al.: Positive ef-fects of large doses of olpadronate (dimethyl-pamidronate) on rat bone structure and biomechanics as assessed by pQCT and bending test. J .Bone Miner. Res. (1994) 9 (Suppl. 1):S396.
   Google Scholar
• MA TF, FERRETTI JL, CAPOZZA RF et al. Effects of on-off anabolic hPTH and remodeling inhibitors on meta-physeal bone of immobilized rat femurs. Tomographi-cal (pQCT) description and correlation with histomorphometric changes in tibial cancellous bone Bone (1995) 17(Suppl 4) S321–5328
   Google Scholar
• MONDELO N, COINTRY G, MONTUORI E, FERRETTI JL: Ensayo tomografico de efectos puros o combinados de hPTH(1-32) y de los bisfosfonatos (BP) pamidronato y olpadronato (APD, OLP) en femur de rata. Medicina (Buenos Aires) (1996) 56:606.
   Google Scholar
• VEGA E, MAUTALEN C, ROLDAN EJA, PEREZ LLORET A: Preliminary study of increasing oral doses of dimethyl APD on bone metabolism dynamics and safety profile. Drugs Exptl. Clin. Res. (1994) 20:103–108.
   PubMedGoogle Scholar
• FABIAN HEM, GIULIANI R, ROLDAN EJA, MONTUORI E: Estudios experimentales del APD-iv sobre la función cardiaca. Acta Physiol. Pharmacol. Lat. Am. (1987) 37:9–10.
   Google Scholar
• ROLDAN EJA, QUATTROCCHI 0, ARAUJO G, PICCINNI E: Aplicación clinica de los principios farmacocinéticos de los bisfosfonatos. Medicina (Buenos Aires) (1997) 57 (Suppl. 0:76–82.
   Google Scholar
• PAPAPOULOS SE, HOEKMAN K, LOWIK WGM, VERMEIJ P, BIJVOET OLM: Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J. Bone Min. Res. (1989) 4:775–781.
   PubMed Web of Science ®Google Scholar
• DEGROSSI 0J, ORTIZ M, DEGROSSI EB et al: Bone scan-ning, serum kinetics and bioavailability of 99m Tc so-dium olpadronate in patients with different bone turnover. Eur. J. Clin. Pharmacol (1995) 48:489–494.
   PubMed Web of Science ®Google Scholar
• DEGROSSI 0J, OLIVERI P, GARCIA DEL RIO H et al: Tech-netium 99m APD compared with technetium 99m MDP as a bone scanning agent. J. Nucl. Med. (1985) 33:1589–1593.
   Google Scholar
• SCHWEITZER DH, ZWINDERMAN AH, VERMEIJ P, BIJVOET OLM, PAPAPOULOS SE: Improved treatment of Paget's bone disease with dimethylaminohydroxypro-pylidene bisphosphonate. J. Bone Min. Res. (1993) 8:175–182.
   PubMed Web of Science ®Google Scholar
• PAPAPOULOS SE, FROLICH M: Prediction of the out-come of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. J. Clin. Endocrinol. Metab. (1996) 81:3993–3997.
   PubMed Web of Science ®Google Scholar
• GONZALEZ D, PASTRANA M, MAUTALEN C: Tratamiento de la enfermedad de Paget con Olpadronato. Su efica-cia terapéutica en respondedores parciales al pa-midronato oral. Medicina (Buenos Aires) (1997) 57 (Suppl. 0:25–31.
   Google Scholar
• PAPAPOULOS SE, VAN HOLTEN-VERZANVOORT ATM: Modulation of tumor-induced bone resorption by bisphosphonates. J. Steroid. Biochem. (1992) 43:131–136.
   Google Scholar
• LANSMEER-BEKER EA, MASSA GG, MAASWINKEL-MOOY PD, VAN KAMP JJP, PAPAPOULOS SE: Treatment of os-teogenesis imperfecta with the bisphosphonate ol-padronate (dimethylaminohydroxypropylidene bisphosphonate). Eur. J. Pediatr. (1997) 156:792–794.
   PubMed Web of Science ®Google Scholar
• BRUMSEN C, HAMDY NA, PAPAPOULOS SE: Long-term effects of bisphosphonates on the growing skeleton studies of young patients with severe osteoporosis. Medicine (1997) 76:266–283.
   PubMed Web of Science ®Google Scholar
• PASQUALINI T, PLANTALECH L, ROLDAN E: A Phase I/II study of pamidronate (APD) in children with osteogenesis imperfecta (00. Acta Physiol. Pharmacol. Therap. Lat. Am. (1996) 46:272.
   Google Scholar
• SCHWEITZER DH, OOSTENDORP-VAN DE RUIT M, VANDER PLUIJM G, LOWIK CWGM, PAPAPOULOS SE: Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylamino-hydroxypropylidene bisphosphonate. J. Bone MM. Res. (1995) 10:956–962.
   PubMed Web of Science ®Google Scholar
• FERRETTI JL, COINTRY GR, CAPOZZA RF et al.: Biome-chanical effects of the full range of useful doses of (3-amino-1 -hydroxyp ropylidene) -1,1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats. Bone Miner. (1990) 11:111–122.
   PubMedGoogle Scholar
• FERRETTI JL, DELGADO CJ, CAPOZZA RF et al: Protectiveeffects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat fe-murs. Bone Miner. (1993) 20:268–276.
   Google Scholar
• FERRETTI JL, MONDELO N, CAPOZZA R et al.: Pa-midronate and dimethylpamidronate effects on femur biomechanicasinovariectomized-hemisciaticectomized rats. Bone Miner. (1992) 17\(Supp1.1):S12.
   Google Scholar
• MILLER SC, JEE WSS, WOODBURY DM, KEMP JW: Effectsof N,N,N',N'-ethylenediaminetetramethylene phos-phonic acid and 1-hydroxyethilidene-1,1-bisphosphonic acid on calcium absorption, plasma calcium, longitudinal bone growth, and bone histol-ogy in the growing rat. Toxicol. Appl. Pharmacol (1985) 77:230–239.
   PubMed Web of Science ®Google Scholar
• SPIVACOW FR, ZANCHETTA JR, KERZBERG EM et al: Tol-erability of oral pamidronate in elderly patients with osteoporosis and other bone diseases. Curr. Ther. Res. (1996) 57:123–130.
   Web of Science ®Google Scholar
• SPIVACOW R, ROLDAN EJA, ZANETTI D, PICCINNI E, ZAN-CHETTA JR: Tolerabilidad de los bisfosfonatos orales en pacientes con osteoporosis y otras osteopatias médicas. Medicina (Buenos Aires) (1997) 57 (Suppl. 1)114–118.
   Google Scholar
• BLANK MA, EMS BL, GIBSON GW et al.: Nonclinical model for assessing gastric effects of bisphosphon-ates. Dig. Dis. ScL (1997) 42:281–288.
   PubMed Web of Science ®Google Scholar
• LUFTKIN EG, ARGUETA R, WHITAKER MD et al: Pa-midronate: an unrecognized problem in gastrointesti-nal tolerability. Osteoporosis InL (1994) 4:320–322.
   PubMed Web of Science ®Google Scholar
• PELGER RCM, HAMDY NAT, ZWINDERMAN AH et al.: Ef-fects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skele-ton. Bone (1998)22:403–408.
   PubMed Web of Science ®Google Scholar
• MONDELO N, ROLDAN EJA, BURG, RUBINSTEIN C, COCO R, MONTUORI: Extraskeletal toxicity of aminobisphos-phonates compounds administered by oral and par-enteral routes. Bone Miner. (1992) 17 (Supp1.1):180.
   Google Scholar
• MONDELO N, PELUFFO VA, PARMA MD et al.: Toxi-cologia preclinica de bisfosfonatos. Medicina (Buenos Aires) (1997) 57\(Suppl. 0:93–100.
   Google Scholar
• BIJVOET OLM: A lifetime of bisphosphonates. Medicina (Buenos Aires) (1997) 57 (Suppl. 1)5–9.
   Google Scholar
• PEREZ LLORET A: Proyecto bisfosfonatos 25 alms de evolución. Medicina (Buenos Aires) (1997) 57 (Suppl. 1)1–4.
   Google Scholar
• VEGA D, BAGGIO R, PIRO 0: Monosodium 3-(dimethyl-ammonio)-1-hydroxy-1,1-propanedyldiphosphonate, monohydrate (monosodium olpadronate monohy-drate). Acta Clystallogr. (1998) 54:324–327.
   PubMed Web of Science ®Google Scholar